NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS

Similar documents
NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA /9/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA /13/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

Prostate Cancer Dashboard

Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template

FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute

General Information. Please silence cell phones. Locations Restrooms to the left of the ballroom, or to your right by the elevators

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR

Commission on Cancer Updates

Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy. Risk Acceptability

PROSTATE CANCER. Mr. Jawad Islam. Consultant Urologist. MBBS, MSc, FRCS(Ed), FEBU, FRCS(Urology) People Centred Positive Compassion Excellence

17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom

4/25/ and Beyond: The Survey Process. The Survey Process Survey Process Task Force

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

Prostate Case Scenario 1

mehealth for ADHD Parent Manual

PCSANM 2015 Seminar. Basic Knowledge: Test for Prostate Cancer. Jerry Cross. 15 item quiz, no grades given

Prostate Cancer Patients Charter. The care that you deserve

The European Board of Urology

Evaluation of Cancer Outcomes Barwon South West Registry

GUIDELINES ON PROSTATE CANCER

Prostate Cancer Local or distant recurrence?

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

C o n t e n t s. 2 Introduction. 3 Personal information. 4 Your medical history. 5 PSA results. 7 Healthcare appointments

NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Illawarra Cancer Care Centre

Attachment #2 Overview of Follow-up

Best Papers. F. Fusco

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Confessions of a Data Quality Manager

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Attachment #2 Overview of Follow-up

MCR MINI UPDATE DECEMBER 2017

Challenging Cases. With Q&A Panel

Prostate Cancer Case Study 2. Medical Student Case-Based Learning

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE

Personalized Therapy for Prostate Cancer due to Genetic Testings

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

1 : Patient Details. 2 : Medical Aid Details. 3 : Practitioner Detail (Practice) 4 : Patient History

Please refer to the specific section of the ecqm to identify the QDM data elements and associated value sets for use in reporting this ecqm.

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Identifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -

PSA is rising: What to do? After curative intended radiotherapy: More local options?

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

National Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network

Mr PHIP No. 4 Life after treatment for localised prostate cancer

Delivering stratified follow-up in primary care for Prostate Cancer Patients - The NCL Approach. Dr Elizabeth Babatunde Macmillan GP

Deciding on treatment: a step on your journey.

ProScript User Guide. Pharmacy Access Medicines Manager

Creating EVENTS in TPN s Partner Portal Step 1: Scroll down to the footer of the home page and click on PARTNER LOGIN:

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

for healthcare professionals

Your Guide to Prostate Cancer

A REPORT ON PRACTICE PATTERN TRENDS IN PROSTATE CANCER

Date Modified: March 31, Clinical Quality Measures for PQRS

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER

The Prostate Perspective. James Lind Alliance Project Emma Halls & Sandy Tyndale-Biscoe

Making the Most of Your Cancer Registry

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

NAACCR Grade 2018 Q & A

Should I get screened for prostate cancer? What you should know about the PSA test

Providing Treatment Information for Prostate Cancer Patients

Helen Forristal MSc (ANP) ; BSc (Hons) Professional Nursing Hormonal Treatment for Prostate Cancer ANP Candidate - Urology 2011

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES

PET imaging of cancer metabolism is commonly performed with F18

The Clinical Research E-News

The Center for Cancer Prevention and Treatment Public Reporting of Outcomes

Prostate Overview Quiz

Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate

PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS

Medication Prior Authorization Form

The Prostate Cancer Surgery Tick List. Use these questions as starters for your first meeting with your prostate cancer surgeon.

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

Troubleshooting Audio

OneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use

ASST Papa Giovanni XXIII

Date Modified: May 29, Clinical Quality Measures for PQRS

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

New research in prostate brachytherapy

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

GREATER BALTIMORE MEDICAL CENTER SANDRA & MALCOLM BERMAN CANCER INSTITUTE

Please submit all questions concerning webinar content through the Q&A panel. Reminder:

PROSTATE CANCER CONTENT CREATED BY. Learn more at

2011 PROSTATE BRACHYTHERAPY STUDY

The Selenium and Vitamin E Prevention Trial

Blue Distinction Centers for Fertility Care 2018 Provider Survey

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Prostate Cancer UK s Best Practice Pathway

If you have aggressive cancer, you would want treatment in time for a cure.

Prostate cancer. A guide for men who ve just been diagnosed

Notes: Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer

Transcription:

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA 2017-040 5/2/17 Eileen Tonner, MS

Purpose of the Study For patients who have received curative-intent prostate cancer treatment Determine whether more frequent PSA testing leads to better survival or more harm for the patient In order to answer this question, it is important to know every PSA test the patient had To know exactly how frequently a patient is having PSA tests To know if the patient has had a recurrence

Thank you for Asking Questions Many questions relate to is this patient eligible? What if I can only get some records for a patient, but not all the records? What if the PCP s office responds but the urologist s office will not respond? The key question is: do you feel you are able to record all the PSAs a patient has had after treatment?

Eligibility Criteria 1) Evidence that medical records are available for the patient for 5 years or until distant recurrence or deathwhichever is first 2) For patients who received primary radical prostatectomy: the patient s urologist and primary care physician can be identified For patients who received primary radiotherapy: the patient s radiation oncologist and urologist and primary care physician can be identified 3) The patients has at least 1 PSA test result within 2 years after end of primary treatment and registrar is confident in capturing PSA information for 2 years after primary treatment completion

PSA PSA intervals can range from monthly or to once a year. There is a wide variation. Registrars should follow the FORDS manual Example: PSA of 1.2, the registrar can enter 012 or 12. Numerically, these are identical numbers and will not affect the study or data analysis. When a patient has a result of <0.03 or <0.01 or <0.2 (less than some number), we would prefer that you enter the result "0" for this special study. In this sole instance we differ from the FORDS manual, and the example was given in the instructions to specifically show this.

Radiation Dose Reminder: Units for Radiation Dose is Gy not cgy 100 cgy = 1 Gy (just like 100 cm = 1 m) If you have already submitted patients in cgy, please send an email to specialstudy@facs.org with your FIN and the Special Study IDs.

Scan Scans that are clearly not related to prostate cancer or prostate cancer recurrence anywhere in the body do not need to be entered. This is different from what is stated in the instructions. We have made modifications based on feedback from registrars.

Testosterone Page 45 typo for units for Total Testosterone values (ng/ml should be ng/dl) For some physicians/hospitals, testosterone testing is routine. For others, it's not. There is variation in clinical practice.

Results of Scan There is no old finding option Example: patient had a bone scan in 2007 which found a spine T7 metastasis, and another bone scan in 2008 which found the same metastasis Please choose new finding (options 3 or 4) as the answer, even though this isn t exactly correct

Web form Some registrars were having issues with the display of the Additional Clinical Information Tab This issue should be resolved now. We do not have the capabilities to allow for printing or sorting patient lists. We suggest taking screenshots.

Study Communication Special Study Website: https://www.facs.org/qualityprograms/cancer/acs-crp/special-study CAnswer Forum and Standards Resource Library: http://cancerbulletin.facs.org/forums/ Please send all study-related questions to specialstudy@facs.org Study related questions sent to personal FACS accounts will be forwarded to the Special Study address and a ticket will be created. EITHER send an email through the Contact form of the website OR email the specialstudy@facs.org email address. Please do not send both as all emails go to the same account. Include FINs in all communication

Email Issues Emails for the special study are being sent from the specialstudy@facs.org email address through an outside server If you have not been receiving these emails, send the following information to your IT department and ask them to put us on the whitelist: IP address: 216.32.180.106, 67.216.228.75

NCRA Webinar Information NCRA 2017-027 Webinar #1 worth 1.0CE 4/11/17 NCRA 2017-029 Webinar #2 worth 1.0CE 4/18/17 NCRA 2017-034 Webinar #3 worth 1.0CE 4/25/17 NCRA 2017-040 Webinar #4 worth 1.0CE 5/02/17

Questions Questions from previous webinar and the Canswer Forum will be included on all webinars. Frequently Asked Questions (FAQ) document will be posted on the website, Canswer Forum, and the web form

Review of FAQs from Previous Webinars

Gleason Score vs. Pattern Q:When you are asking for the primary biopsy Gleason score and the secondary biopsy Gleason score are you really referring to the primary and secondary pattern? My patient had primary biopsy Gleason score already populated with a 4. Secondary biopsy Gleason score populated with a 3. The score, to me, is the combination of the primary/secondary pattern. A: Both score and pattern are used and are meant to describe the same thing. In this case, Primary Biopsy Gleason Score is 4 and Secondary Biopsy Gleason Score is 3.

Recurrence 1. What PSA level should be used to classify a patient as having recurrence? We are not asking registrars to interpret PSA results Please record recurrence if clinical notes indicate recurrence, and/or if patient receives treatment for recurrence 2. Does the patient have recurrence if he was never disease free after treatment? Yes. Please record the date of first PSA test after primary treatment as date of recurrence.

Recurrence Q: Patient with a regional recurrence with treatment which progressed to distant metastasis? Do you want both recorded and if so which one do you want the treatment for? A: For recurrence as a whole (biochemical, local, regional, distant), we ask that you capture the first instance of each type of treatment received: hormone therapy, RT, surgery, chemotherapy etc., if the patient received these types of treatments.

What should I do if a physician s office does not respond to record requests? If the record request form was faxed, call the office directly to request the records Make sure to send the letter template for patient information from the CoC so the office is aware this data is required for CoC accreditation

What if the urologist and PCP are retired? Please see if possible to collect records from their offices. Often, physicians may have retired but records are still available All NPIs are required for each provider If the NPI on the Surveillance tab is unknown: 00000000 if there is no provider 99999999 if they have the provider, but the NPI is completely unknown 77777777 if it is unknown whether they have this provider.

NCDB Data Q: Comparing what information the NCDB tab has for a patient to what the medical record contains, there is more information available in the medical record than was initially abstracted. (i.e. Gleason on Prostatectomy and Date of Last Contact). A: Please select No and fill in the updated information. We are looking for the most current data.